Clinical Trials Search
Clinical Trial 19342
Interventions:Pembrolizumab (Keytruda); SAHA (Vorinostat); Temodal (Temozolomide); Temozolomide; Vorinostat; Zolinza (Vorinostat); suberoylanilide hydroxamic acid (Vorinostat)
Study Type: Treatment
Phase of Study: Phase I
- Solmaz Sahebjam
A Phase I Trial of Pembrolizumab and Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy (temozolomide), and radiotherapy.
Primary: To evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) of pembrolizumab given in combination with vorinostat, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma. Secondary:: To evaluate the 12 months and 24 months survival rate in patients with newly diagnosed glioblastoma who are treated with pembrolizumab in combination with vorinostat and standard treatment with radiotherapy and temozolomide. Exploratory: To explore tissue and blood biomarkers that may predict tumor response to pembrolizumab in combination with vorinostat and standard treatment with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.